DNTH
DNTH
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
22
$83.13M
Total Volume
$83.13M
38 transactions
Net Activity
$83.13M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Garcia Marino
CEO, Pres
$27.96M total
Savitz Ryan
EVP, CFO, CBO
$26.22M total
Randhawa Simrat
EVP, Head of R, D
$15.00M total
Carr Edward
CHIEF ACCOUNTING OFFICER
$5.59M total
Veness Adam M
SVP, GC, Sec.
$4.63M total
Quick Actions
DNTH has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. DNTH ranks #131 in insider activity out of 570 tracked companies in its industry.
Over the last 90 days, corporate insiders at DNTH (DNTH) engaged in a total of 38 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 22 were sales. The total volume of insider trading reached $83.13M.
The net insider activity for DNTH shows a net selling bias of $83.13M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Garcia Marino (CEO, Pres), who traded 166.0K shares valued at $17.95M on Aug 7, 2026.
Dianthus Therapeutics (DNTH) Stock May Look Stretched As Pipeline Progress Draws Focus
DNTH - Dianthus Therapeutics Inc Stock Price and Quote
Dianthus Therapeutics (NASDAQ:DNTH) Shares Cross Below 50-Day Moving Average - Here's What Happened
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
$DNTH stock is down 15% today. Here's what we see in our data.
Dianthus (NASDAQ: DNTH) officer set to sell 20,000 shares
FAQs About DNTH Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for DNTH.